about
Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administrationStratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.Liver involvement in cystic fibrosis.Presence of fetal DNA in maternal plasma decades after pregnancy.Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease.Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosisEvolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary CholangitisClinical features and management of primary biliary cirrhosis.Is autoimmunity a matter of sex?Novel soy germ pasta enriched in isoflavones ameliorates gastroparesis in type 2 diabetes: a pilot study.Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions.ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.Hepatitis C virus testing in primary biliary cirrhosis.Lack of association between circulating HCV-RNA and anti-HCV positivity in primary biliary cirrhosis.Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies.Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis.Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion.Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.Acute liver and renal failure during treatment with buprenorphine at therapeutic dose.Complement system is not activated in primary biliary cirrhosis.Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis.Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.Insulin secretion, nutritional status and respiratory function in cystic fibrosis patients with normal glucose tolerance.Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.X monosomy in female systemic lupus erythematosus.Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis.Blood fetal microchimerism in primary biliary cirrhosis.Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis.MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation.Frequency of monosomy X in women with primary biliary cirrhosis.Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary CirrhosisMulticentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosisPBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosisAntibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status
P50
Q28334026-64548561-8CA5-4D20-9593-413062CD4B6AQ33419647-170AC990-1B21-40A8-AEC6-F591B4CD2BCFQ33784011-C44E235E-73F6-4DB5-940D-09283D6F5487Q34137715-152FA45C-946D-4F91-BA13-22E4C43C3DB2Q35157250-FE6556BB-40C3-4E85-8FDE-249DBEB730FEQ35594898-A7BFC214-CDA7-4F80-B155-6AAD529449A0Q36914749-163EEEA7-D91F-4C89-A626-D69A09C667B2Q37182934-001A7FF3-A4E0-4723-9582-B5FAEC8933BEQ37207818-2EC7FEE8-D959-4A02-80CA-42098627A431Q37277907-068A37E1-0A50-4A79-AC70-0B35D7392EF1Q38413146-78450BE7-C52D-4988-9F53-56E34E745827Q39245295-92B52AE1-D325-42B2-A8F1-387A5949B76FQ40589408-CB79667B-0F3E-472F-8EF0-EC8113ED8CCDQ42981793-CF48E102-2AA0-4CEE-B815-3287D97AA41EQ42985326-7231AF7E-68AB-436B-A144-1378B707E9C5Q43032576-3DC0B68A-8F19-4E31-8C8F-26C7E9D321A2Q43040184-9D1D0151-4352-40A2-A3FD-7E2AD93A5D7AQ43049090-3A3BF3B2-76DA-4583-9653-204583BAD19BQ43471968-182F6649-D32C-4A65-9292-AEB462758628Q43478375-F8340FD2-E22C-40BA-BB38-740DE9AB5BC7Q43518208-B543FE49-74DF-48BC-AFA7-BCFFF11518FCQ43734578-78C7EDA3-0D90-4D21-AC79-8FAA63F915AEQ46737651-8222ADA5-EF46-4E0D-81BF-BE4F3398240EQ47911204-7B2953CB-7C62-4578-B4FD-B775EAB37F3CQ48007481-112465EB-55DD-4446-A7DC-333EAB471E4BQ50561780-9FC5C684-3015-4582-B2B4-8E3505762747Q51149200-749A6543-A169-4E2E-B199-5B803298DADBQ51367161-7F30204E-1958-403C-A0E2-1A75C30A60DEQ51604167-DB72EA71-F2FB-45CE-8CA1-925CEA5F64B6Q51734491-EBEC4814-8312-4AEE-9ACD-E3C2CA34EFBEQ51770188-824F9117-A835-4615-A72A-CAF8B6398CEBQ53748681-D6841E33-652B-4FDB-80C0-2752904DD6BAQ54384963-71BE461D-C177-4D14-9A05-C2A820C4D51BQ54407451-84DF9C7D-A61B-4F16-ABF3-E52C9BDC1BD6Q55038191-627A258F-EE1D-4AB9-8D9A-F656559800CDQ55041843-6C0A63E3-3046-4308-9312-25B59EB2E4DCQ57719353-EDDDC66D-7111-4285-9F0B-217DC66C1D84Q58803462-718F24F6-EB8A-4287-8F59-648B899404F8Q59384457-5E5146AF-C485-462A-9DCD-5CC7E3417DFDQ62395194-646F6C43-7E74-4941-9653-EB08444D3FD6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pier Maria Battezzati
@ast
Pier Maria Battezzati
@en
Pier Maria Battezzati
@es
Pier Maria Battezzati
@sl
type
label
Pier Maria Battezzati
@ast
Pier Maria Battezzati
@en
Pier Maria Battezzati
@es
Pier Maria Battezzati
@sl
prefLabel
Pier Maria Battezzati
@ast
Pier Maria Battezzati
@en
Pier Maria Battezzati
@es
Pier Maria Battezzati
@sl
P106
P1153
7004451577
P21
P31
P496
0000-0003-1344-3452